Zimbabwe has declined a substantial American healthcare agreement valued at $367m (272 million pounds) over five years due to Washington's demand for sensitive biological samples.
This move came to light after a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "skewed".
An official spokesman has since stated that the US was requesting health data for scientific study and commercial purposes while refused to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more dialogue to secure a agreement agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Context
Zimbabwe's decision follows a similar case in Kenya, where a court suspended a related health funding agreement following legal challenges were raised about the security of Kenyans' medical information.
After resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
According to statements, Sixteen nations in Africa have so far signed similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, with no equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our population if a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting frameworks previously established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This mechanism is designed to guarantee that when a country provides its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our US partners on how future co-operation could be arranged in a manner that respects the independence and dignity of both nations."
Medical Community Response
A leading public health body stated it understood the government's concerns, but recommended that talks should continue since much of the nation's Aids initiatives relied on foreign aid.
"If technical issues arise, including those involving information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the complex debate between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.